Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
Schoppert Wendy Lee reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Wendy L. Schoppert reported a compensation-related stock grant and updated holdings. She received an award of 250 shares of DaVita common stock at $0.0000 per share, bringing her directly held common stock to 250 shares.
The filing also reports 3,637 shares of common stock held indirectly through the Wendy L. Schoppert Revocable Trust after the reported date. No open-market purchases or sales were reported in this filing.
Arway Pamela M reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Pamela M. Arway reported receiving a grant of 250 shares of DaVita common stock on May 15, 2026. The shares were awarded at a stated price of $0.00 per share, indicating a compensation-related stock award rather than an open-market purchase.
Following this grant, Arway directly holds 26,945 shares of DaVita common stock. This filing reflects a small, routine equity award that modestly increases her direct ownership stake in the company.
DaVita Inc. director Phyllis R. Yale received 250 shares of Common Stock as a grant or award, with no cash price per share reported. This non-derivative acquisition increased her direct holdings to 14,563 DaVita shares, reflecting routine equity-based compensation rather than an open-market purchase.
DESOER BARBARA J reported acquisition or exercise transactions in this Form 4 filing.
DAVITA INC. director Barbara J. Desoer reported a compensation-related stock grant. She received 250 shares of Common Stock as a grant or award at a stated price of $0.00 per share, bringing her directly held position to 250 shares.
The filing also shows 13,771 shares of Common Stock held indirectly through the “Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998,” reflecting additional beneficial ownership reported via a trust structure.
Schechter Adam H reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Adam H. Schechter received a grant of 250 shares of DaVita common stock on May 15, 2026. The shares were awarded at a price of $0.00 per share, indicating a compensation-related equity award rather than a market purchase. Following this grant, Schechter directly holds 5,692 shares of DaVita common stock.
DaVita Inc. director Jason M. Hollar reported receiving a grant of 250 shares of Common Stock on May 15, 2026. The shares were acquired at a reported price of $0.00 per share, indicating a compensation-related award rather than a market purchase. Following this grant, Hollar directly holds 6,605 shares of DaVita common stock. This filing reflects routine equity compensation and does not show any open-market buying or selling activity.
DaVita Inc.’s Chief Compliance Officer James O. Hearty reported an option-style exercise and subsequent stock sale. On May 14, 2026, he exercised 5,784 Stock Appreciation Rights at $110.63 per share, receiving common stock. Of these shares, 3,231 were withheld to pay the base price and 1,117 were withheld to cover tax obligations.
On May 15, 2026, he completed an open-market sale of 15,000 DaVita common shares at a weighted average price of $193.983, within a price range of $193.360–$199.840. Following these transactions, he directly owns 22,389 DaVita common shares.
DaVita Inc. (DVA) notice of proposed sale reports employee RSU vesting entries and a recent sale. The filing lists multiple vested RSU lots by vesting date and quantity and records 2,184 shares sold on 05/06/2026 in the past three months. The listed vesting entries show scheduled cash-settled awards across dates from 02/21/2014 to 05/14/2026.
DaVita Inc. Chief Operating Officer David Paul Maughan reported two open-market stock sales. On May 11, he sold 7,073 shares of DaVita common stock at a weighted average price of $199.149 per share. On May 12, he sold an additional 13,456 shares at a weighted average price of $199.254 per share. After these transactions, he directly owns 94,105 DaVita shares, so he continues to hold a substantial position in the company.
DaVita Inc. submitted a Form 144 notice listing proposed sales of common stock tied to employee equity events. The excerpt itemizes planned dispositions from ESPP purchases and restricted stock vesting with sample lot sizes of 307, 5,711, 165, and 14,346 shares on the dates shown.